Processa Pharmaceuticals, Inc. (PCSA) Stock

Processa Pharmaceuticals, Inc. (PCSA) is a Healthcare stock trading at $2.03 (as of 2026-08-21), with a market capitalization of $5.67M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for treating conditions with unmet medical needs in the United States. Its pipeline includes PCS499 for necrobiosis lipoidica, PCS12852 for gastrointestinal disorders, PCS3117 for certain cancers, and other oncology and gastrointestinal candidates in early-to-mid clinical stages.

Understand Processa Pharmaceuticals, Inc.: how it makes money

Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing drug products for unmet medical needs, with lead candidates PCS499 (oral tablet) in Phase 2B trials for necrobiosis lipoidica and PCS12852 in Phase 2A trials for gastroparesis and chronic constipation; the provided facts do not describe how it currently makes money.

Its profit model depends on advancing trial-stage drug candidates, since the companys key assets in the provided facts are PCS499 (Phase 2B) and PCS12852 (Phase 2A).

Business quality (Weak): Limited provided operating detail beyond pipeline phase and a quarter showing 0.0 revenue and a very negative operating margin, so near-term fundamentals cannot be assessed beyond clinical and expense risk.

Bull case

  • Pipeline focus on unmet medical needs: Lead candidate PCS499 is in Phase 2B clinical trials for ulcerative and non-ulcerative necrobiosis lipoidica, and PCS12852 is in Phase 2A for gastroparesis and chronic constipation.

Bear case

  • No revenue reported in the latest provided quarter: For the period ending 2026-03-31, revenue is shown as 0.0B in the provided facts.
  • Very large operating loss in the latest provided quarter: Operating margin is shown as -24036.5 for the period ending 2026-03-31, indicating substantial operating losses.
Valuation — source: SEC EDGAR (first-party)
Price$2.03
Market Cap$5.67M
Price / Sales140.70
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$109491.00
Net Margin-12388.1%
Revenue Growth (YoY)-45.6%
EPS Growth (YoY)167.7%
Financial Health — source: SEC EDGAR
Altman Z-Score-21.93 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderConnective Capital Management, LLC ($178608.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGeorge K. Ng
Employees10
CountryUS
IPO Date2014-03-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Xenetic Biosciences, Inc. (XBIO)
  • Apimeds Pharmaceuticals US, Inc (APUS)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Enveric Biosciences, Inc. (ENVB)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • PMGC Holdings Inc. (ELAB)
  • AEON Biopharma, Inc. (AEON)
PCSA earnings history · PCSA institutional & insider holders · PCSA KPIs & operating metrics · PCSA financials · PCSA investor presentations & press releases · PCSA SEC filings · PCSA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.